novavax
| 3:30PM 3/01/2011
The company has landed a lucrative flu-vaccine contract with the U.S. government. It's worth $97 million over the first three years, and it can be extended for an additional two years, for a total contract value of $179.1 million. The technology could prove to be a lifesaver.
| 4:50PM 12/02/2009
A biotech with a novel method of making vaccines, has a promising swine flu drug. So far, so good, but it's hardly a lock
| 4:30PM 10/26/2009
President Obama declared the H1N1 flu outbreak a national emergency last weekend. While U.S. officials insist the move is not a reaction to new developments but a preventive measure, it comes just as the vaccine shortage has been making headlines, with the Centers for Disease Control "frustrated"...
| 4:40PM 9/01/2009
Two weeks ago, Novavax (NVAX) shares soared some 10 percent after the small clinical-stage biotechnology company announced positive preclinical results for its new vaccine against H1N1 influenza. Shares jumped again today -- this time about 15 percent by late-afternoon trading -- after the vaccine...
| 4:45PM 8/18/2009
Novavax (NVAX) shares soared some 10 percent today after the small clinical-stage biotechnology company announced positive preclinical results for its new vaccine H1N1 influenza, or swine flu.
Novovax, based in Rockville, Maryland, developed the vaccine using proprietary virus-like particle (VLP)...